Switch to:
Also traded in: Germany, Switzerland

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.50
QGEN's Cash-to-Debt is ranked lower than
76% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.44 vs. QGEN: 0.50 )
Ranked among companies with meaningful Cash-to-Debt only.
QGEN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.34  Med: 0.87 Max: 2.92
Current: 0.5
0.34
2.92
Equity-to-Asset 0.61
QGEN's Equity-to-Asset is ranked higher than
53% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. QGEN: 0.61 )
Ranked among companies with meaningful Equity-to-Asset only.
QGEN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.47  Med: 0.61 Max: 0.7
Current: 0.61
0.47
0.7
Interest Coverage 2.46
QGEN's Interest Coverage is ranked lower than
88% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 54.16 vs. QGEN: 2.46 )
Ranked among companies with meaningful Interest Coverage only.
QGEN' s Interest Coverage Range Over the Past 10 Years
Min: 2.05  Med: 4.01 Max: 7.24
Current: 2.46
2.05
7.24
Piotroski F-Score: 4
Altman Z-Score: 3.31
Beneish M-Score: -2.76
WACC vs ROIC
8.24%
2.90%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 7.18
QGEN's Operating Margin % is ranked higher than
62% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. QGEN: 7.18 )
Ranked among companies with meaningful Operating Margin % only.
QGEN' s Operating Margin % Range Over the Past 10 Years
Min: 4.86  Med: 13.17 Max: 17.85
Current: 7.18
4.86
17.85
Net Margin % 5.85
QGEN's Net Margin % is ranked higher than
68% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.64 vs. QGEN: 5.85 )
Ranked among companies with meaningful Net Margin % only.
QGEN' s Net Margin % Range Over the Past 10 Years
Min: 5.31  Med: 9.3 Max: 13.64
Current: 5.85
5.31
13.64
ROE % 2.99
QGEN's ROE % is ranked higher than
54% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.95 vs. QGEN: 2.99 )
Ranked among companies with meaningful ROE % only.
QGEN' s ROE % Range Over the Past 10 Years
Min: 2.54  Med: 4.9 Max: 7.36
Current: 2.99
2.54
7.36
ROA % 1.86
QGEN's ROA % is ranked higher than
60% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.53 vs. QGEN: 1.86 )
Ranked among companies with meaningful ROA % only.
QGEN' s ROA % Range Over the Past 10 Years
Min: 1.69  Med: 2.84 Max: 4.12
Current: 1.86
1.69
4.12
ROC (Joel Greenblatt) % 13.33
QGEN's ROC (Joel Greenblatt) % is ranked higher than
59% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.23 vs. QGEN: 13.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
QGEN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 10.34  Med: 26.26 Max: 45.62
Current: 13.33
10.34
45.62
3-Year Revenue Growth Rate 1.40
QGEN's 3-Year Revenue Growth Rate is ranked lower than
56% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.20 vs. QGEN: 1.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
QGEN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 1.2  Med: 9 Max: 36.2
Current: 1.4
1.2
36.2
3-Year EBITDA Growth Rate 5.40
QGEN's 3-Year EBITDA Growth Rate is ranked higher than
61% of the 119 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.00 vs. QGEN: 5.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
QGEN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -8.2  Med: 13.3 Max: 40.7
Current: 5.4
-8.2
40.7
3-Year EPS without NRI Growth Rate 5.50
QGEN's 3-Year EPS without NRI Growth Rate is ranked higher than
62% of the 110 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.50 vs. QGEN: 5.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
QGEN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -21.5  Med: 11.3 Max: 38.9
Current: 5.5
-21.5
38.9
GuruFocus has detected 3 Warning Signs with Qiagen NV $QGEN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» QGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

QGEN Guru Trades in Q1 2016

George Soros 78,400 sh (New)
Oakmark Intl Small Cap 1,451,000 sh (+671.81%)
Manning & Napier Advisors, Inc 4,641,049 sh (+62.42%)
PRIMECAP Management 20,493,375 sh (-0.19%)
Jim Simons 174,597 sh (-16.95%)
» More
Q2 2016

QGEN Guru Trades in Q2 2016

Paul Tudor Jones 16,200 sh (New)
Oakmark Intl Small Cap 2,323,000 sh (+60.10%)
Manning & Napier Advisors, Inc 6,111,364 sh (+31.68%)
Jim Simons Sold Out
George Soros Sold Out
PRIMECAP Management 20,128,325 sh (-1.78%)
» More
Q3 2016

QGEN Guru Trades in Q3 2016

Jim Simons 190,000 sh (New)
Steven Cohen 294,400 sh (New)
Paul Tudor Jones 17,000 sh (+4.94%)
PRIMECAP Management 19,473,847 sh (-3.25%)
Manning & Napier Advisors, Inc 5,295,154 sh (-13.36%)
Oakmark Intl Small Cap 1,666,000 sh (-28.28%)
» More
Q4 2016

QGEN Guru Trades in Q4 2016

Jim Simons 535,400 sh (+181.79%)
PRIMECAP Management 19,143,036 sh (-1.70%)
Paul Tudor Jones 16,373 sh (-3.69%)
Manning & Napier Advisors, Inc 4,832,166 sh (-8.74%)
Steven Cohen 260,400 sh (-11.55%)
» More
» Details

Insider Trades

Latest Guru Trades with QGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325414 
Compare:OTCPK:BMXMF, NAS:DXCM, NYSE:PKI, OTCPK:ERFSF, NYSE:BIO.B, NAS:ICLR, NYSE:CRL, NAS:BRKR, NAS:PRAH, NYSE:ALR, OTCPK:CZMWY, NAS:PRXL, NAS:NEOG, NAS:EXAS, NAS:AXDX, NAS:MYGN, NAS:ABAX, NAS:ALOG, NAS:GHDX, NAS:FMI » details
Traded in other countries:QIA.Germany, QGEN.Switzerland,
Qiagen NV provides sample and assay technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics.

Qiagen NV provides Sample & Assay Technologies, based on market studies of United States and European market shares for its products and technologies. It also offers kits, assays, related automated systems and bioinformatics solutions, that cover the entire continuum from basic life sciences research to clinical diagnostics. The Company markets more than 500 core products that are distributed in thousands of variations and combinations. In October 2012, the company announced a collaboration with Bayer HealthCare for development and commercialization of companion diagnostics paired with novel Bayer drugs, initially to enhance the treatment of various solid tumors. The Company has developed and advanced a broad range of technologies to extract and purify molecules of interest from biological samples such as blood, bone, tissue. It has also developed assays that enable the analysis of various kinds of molecules from virtually any biological sample. Assay technologies make information contained in isolated molecules visible and available for interpretation. The Company sells varied and flexible workflows for molecular testing, including sample and assay kits known as consumables and automated instrumentation platforms using those technologies, to four major customer classes: Molecular Diagnostics - healthcare providers supporting many aspects of patient care including prevention, profiling of diseases, personalized healthcare and point of need testing; Applied Testing - government or industry customers using molecular technologies in fields such as forensics, veterinary diagnostics and food safety testing; Pharma - drug discovery, translational medicine and clinical development efforts of pharmaceutical and biotechnology companies; Academia - researchers exploring the secrets of life such as the mechanisms and pathways of diseases. The Company markets its products in more than 100 countries throughout the world. The Company's competitors includes Promega Corp., EMD Millipore or Merck Millipore, and Macherey-Nagel GmbH for nucleic acid separation and purification; Thermo Fisher and Promega Corp. for assay solutions and for transfection reagents; and Sigma-Aldrich Corp. and Thermo Fisher for protein fractionation products. The Company is subject to a variety of laws and regulations in the European Union, the United States and other countries.

Ratios

vs
industry
vs
history
PE Ratio 82.76
QGEN's PE Ratio is ranked lower than
92% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.23 vs. QGEN: 82.76 )
Ranked among companies with meaningful PE Ratio only.
QGEN' s PE Ratio Range Over the Past 10 Years
Min: 22.58  Med: 39.15 Max: 154.18
Current: 82.76
22.58
154.18
Forward PE Ratio 22.73
QGEN's Forward PE Ratio is ranked lower than
52% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.08 vs. QGEN: 22.73 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 82.76
QGEN's PE Ratio without NRI is ranked lower than
92% of the 78 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.37 vs. QGEN: 82.76 )
Ranked among companies with meaningful PE Ratio without NRI only.
QGEN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 22.27  Med: 39.75 Max: 160.79
Current: 82.76
22.27
160.79
Price-to-Owner-Earnings 45.31
QGEN's Price-to-Owner-Earnings is ranked lower than
68% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.26 vs. QGEN: 45.31 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
QGEN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 16.09  Med: 36.56 Max: 206.79
Current: 45.31
16.09
206.79
PB Ratio 2.43
QGEN's PB Ratio is ranked higher than
66% of the 143 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.51 vs. QGEN: 2.43 )
Ranked among companies with meaningful PB Ratio only.
QGEN' s PB Ratio Range Over the Past 10 Years
Min: 1.16  Med: 2.14 Max: 4.79
Current: 2.43
1.16
4.79
PS Ratio 4.82
QGEN's PS Ratio is ranked lower than
64% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.05 vs. QGEN: 4.82 )
Ranked among companies with meaningful PS Ratio only.
QGEN' s PS Ratio Range Over the Past 10 Years
Min: 2.71  Med: 4.33 Max: 6.52
Current: 4.82
2.71
6.52
Price-to-Free-Cash-Flow 26.08
QGEN's Price-to-Free-Cash-Flow is ranked higher than
52% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 28.89 vs. QGEN: 26.08 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
QGEN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 20.03  Med: 33.07 Max: 174.14
Current: 26.08
20.03
174.14
Price-to-Operating-Cash-Flow 18.90
QGEN's Price-to-Operating-Cash-Flow is ranked higher than
51% of the 74 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.95 vs. QGEN: 18.90 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
QGEN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.11  Med: 19.84 Max: 56.08
Current: 18.9
12.11
56.08
EV-to-EBIT 76.20
QGEN's EV-to-EBIT is ranked lower than
95% of the 77 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.75 vs. QGEN: 76.20 )
Ranked among companies with meaningful EV-to-EBIT only.
QGEN' s EV-to-EBIT Range Over the Past 10 Years
Min: 17.5  Med: 33.5 Max: 93
Current: 76.2
17.5
93
EV-to-EBITDA 27.03
QGEN's EV-to-EBITDA is ranked lower than
86% of the 83 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 15.68 vs. QGEN: 27.03 )
Ranked among companies with meaningful EV-to-EBITDA only.
QGEN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.6  Med: 16.4 Max: 31.4
Current: 27.03
9.6
31.4
PEG Ratio 46.00
QGEN's PEG Ratio is ranked lower than
100% of the 39 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.09 vs. QGEN: 46.00 )
Ranked among companies with meaningful PEG Ratio only.
QGEN' s PEG Ratio Range Over the Past 10 Years
Min: 1.65  Med: 2.84 Max: 765.67
Current: 46
1.65
765.67
Shiller PE Ratio 54.27
QGEN's Shiller PE Ratio is ranked lower than
69% of the 29 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 40.04 vs. QGEN: 54.27 )
Ranked among companies with meaningful Shiller PE Ratio only.
QGEN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 27.96  Med: 48.43 Max: 84.46
Current: 54.27
27.96
84.46
Current Ratio 3.36
QGEN's Current Ratio is ranked higher than
63% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.70 vs. QGEN: 3.36 )
Ranked among companies with meaningful Current Ratio only.
QGEN' s Current Ratio Range Over the Past 10 Years
Min: 1.65  Med: 3.13 Max: 5.86
Current: 3.36
1.65
5.86
Quick Ratio 2.92
QGEN's Quick Ratio is ranked higher than
62% of the 154 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. QGEN: 2.92 )
Ranked among companies with meaningful Quick Ratio only.
QGEN' s Quick Ratio Range Over the Past 10 Years
Min: 1.36  Med: 2.54 Max: 5.31
Current: 2.92
1.36
5.31
Days Inventory 104.51
QGEN's Days Inventory is ranked lower than
64% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 75.58 vs. QGEN: 104.51 )
Ranked among companies with meaningful Days Inventory only.
QGEN' s Days Inventory Range Over the Past 10 Years
Min: 98.81  Med: 112.97 Max: 128.65
Current: 104.51
98.81
128.65
Days Sales Outstanding 75.90
QGEN's Days Sales Outstanding is ranked lower than
63% of the 126 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. QGEN: 75.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
QGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.73  Med: 72.41 Max: 78.03
Current: 75.9
63.73
78.03
Days Payable 37.88
QGEN's Days Payable is ranked lower than
65% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.14 vs. QGEN: 37.88 )
Ranked among companies with meaningful Days Payable only.
QGEN' s Days Payable Range Over the Past 10 Years
Min: 35.09  Med: 45.07 Max: 68.16
Current: 37.88
35.09
68.16

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 50.98
QGEN's Price-to-Tangible-Book is ranked lower than
99% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.83 vs. QGEN: 50.98 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
QGEN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.36  Med: 15.04 Max: 156.15
Current: 50.98
3.36
156.15
Price-to-Intrinsic-Value-Projected-FCF 1.75
QGEN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
60% of the 68 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. QGEN: 1.75 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
QGEN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.01  Med: 1.85 Max: 32.12
Current: 1.75
1.01
32.12
Price-to-Intrinsic-Value-DCF (Earnings Based) 7.73
QGEN's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked lower than
100% of the 16 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.75 vs. QGEN: 7.73 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.11
QGEN's Price-to-Median-PS-Value is ranked higher than
50% of the 130 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.11 vs. QGEN: 1.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
QGEN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.58  Med: 1.11 Max: 5.15
Current: 1.11
0.58
5.15
Price-to-Graham-Number 13.46
QGEN's Price-to-Graham-Number is ranked lower than
100% of the 51 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.68 vs. QGEN: 13.46 )
Ranked among companies with meaningful Price-to-Graham-Number only.
QGEN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.2  Med: 7.15 Max: 18.45
Current: 13.46
2.2
18.45
Earnings Yield (Greenblatt) % 1.30
QGEN's Earnings Yield (Greenblatt) % is ranked higher than
52% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.00 vs. QGEN: 1.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
QGEN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.1  Med: 3 Max: 5.7
Current: 1.3
1.1
5.7
Forward Rate of Return (Yacktman) % 5.27
QGEN's Forward Rate of Return (Yacktman) % is ranked lower than
57% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.86 vs. QGEN: 5.27 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
QGEN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2.3  Med: 14.6 Max: 19.8
Current: 5.27
-2.3
19.8

More Statistics

Revenue (TTM) (Mil) $1,338
EPS (TTM) $ 0.34
Beta1.14
Short Percentage of Float1.82%
52-Week Range $20.71 - 30.09
Shares Outstanding (Mil)225.57

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 1,418 1,492
EPS ($) 1.25 1.40
EPS without NRI ($) 1.25 1.40
EPS Growth Rate
(Future 3Y To 5Y Estimate)
9.12%
Dividends per Share ($)
» More Articles for NAS:QGEN

Headlines

Articles On GuruFocus.com
David Herro's Oakmark International Small Cap Fund 4th Quarter Commentary Jan 08 2016 
Biotech Gets Personal: Long on Qiagen (QGEN) & SPDR S&P Biotech (XBI) Feb 29 2012 
Guru Stocks at 52-Week Lows: LMT, VIP, VMC, IRM, QGEN Oct 10 2010 
Weekly Guru Bargains Highlights: QGEN, BXS, ATHR, LYV, TFSL Oct 09 2010 

More From Other Websites
New Study Published in Lancet Respiratory Medicine Highlights QIAGEN's QuantiFERON-TB Potential to... Feb 16 2017
QIAGEN NV :QGEN-US: Earnings Analysis: 2016 By the Numbers : February 8, 2017 Feb 08 2017
QIAGEN NV :QGEN-US: Earnings Analysis: Q4, 2016 By the Numbers : February 6, 2017 Feb 06 2017
QIAGEN (QGEN) Earnings Meet, Sales Miss Estimates in Q4 Feb 03 2017
Edited Transcript of QGEN earnings conference call or presentation 2-Feb-17 2:00pm GMT Feb 02 2017
Qiagen meets 4Q profit forecasts Feb 01 2017
Qiagen meets 4Q profit forecasts Feb 01 2017
QIAGEN Reports Results for Fourth Quarter and Full-year 2016 Feb 01 2017
QIAGEN NV breached its 50 day moving average in a Bullish Manner : QGEN-US : February 1, 2017 Feb 01 2017
Q4 2016 Qiagen NV Earnings Release - 4:00 pm ET Feb 01 2017
QIAGEN Hereditary and Rare Disease Solution Chosen by Genomics England Jan 30 2017
QIAGEN's QuantiFERON-TB Test Wins Tender for Testing of Republic of Korea Armed Forces Recruits Jan 26 2017
QIAGEN Announces Adjustment of Conversion Ratio Under its 0.375% Senior Unsecured Convertible Notes... Jan 26 2017
QIAGEN NV – Value Analysis (NASDAQ:QGEN) : January 19, 2017 Jan 19 2017
QIAGEN Announces Details for Completion of Approximately $250 Million Synthetic Share Repurchase Jan 18 2017
QIAGEN NV breached its 50 day moving average in a Bearish Manner : QGEN-US : January 18, 2017 Jan 18 2017
QIAGEN N.V. to Report Fourth Quarter and Full Year of 2016 Results Jan 18 2017
Singulex Enters into Collaboration with QIAGEN to Develop Companion Diagnostics Jan 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)